Astrana Health, Inc. 8-K

What Happened
Astrana Health, Inc. announced results of its Annual Meeting held June 10, 2026 and filed an 8-K reporting that stockholders approved an Amended and Restated 2024 Equity Incentive Plan and elected nine directors. The 2024 Plan was amended to increase the number of shares reserved by 1,000,000 and the plan term was extended to March 24, 2036. The Company also ratified Ernst & Young LLP as its independent registered public accounting firm and received an advisory (non‑binding) approval of its executive compensation disclosure.

Key Details

• Record date and turnout: 55,713,532 shares outstanding as of April 14, 2026; 43,772,595 shares represented at the meeting (~78.6%), constituting a quorum.
• 2024 Equity Incentive Plan: increased by 1,000,000 shares and extended through March 24, 2036; plan document filed as Exhibit 10.1.
• Directors elected (to hold office until 2027 Annual Meeting): Kenneth Sim, M.D.; Thomas S. Lam, M.D., M.P.H.; John Chiang; Weili Dai; Linda Dong; J. Lorraine Estradas, R.N., B.S.N., M.P.H.; Mitchell W. Kitayama; Matthew Mazdyasni; David G. Schmidt.
• Key vote tallies:
  • Approval of 2024 Plan: 34,679,879 For / 701,303 Against / 35,295 Abstain (8,356,118 broker non‑votes).
  • Advisory vote on executive compensation: 34,119,199 For / 1,209,072 Against / 88,206 Abstain (8,356,118 broker non‑votes).
  • Ratification of Ernst & Young LLP: 43,722,509 For / 19,566 Against / 30,520 Abstain.

Why It Matters
Approval of the amended equity plan gives Astrana Health authority to grant more stock‑based awards (1,000,000 additional shares) and extends the period during which those awards can be issued, which affects potential future dilution depending on grant and exercise activity. Election of the nine directors and ratification of the auditor support board continuity and audit firm continuity. The advisory say‑on‑pay passed, indicating shareholder support for the company's executive compensation disclosures (non‑binding). Investors should watch future SEC filings for specific grant activity under the amended plan, which will show any actual dilution and the timing of awards.